River Road Asset Management LLC grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 917,717 shares of the biopharmaceutical company’s stock after buying an additional 177,620 shares during the period. River Road Asset Management LLC owned 0.06% of Bristol-Myers Squibb worth $46,537,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Nuveen Asset Management LLC raised its holdings in shares of Bristol-Myers Squibb by 14,860.1% during the second quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock valued at $426,069,000 after buying an additional 9,332,319 shares during the last quarter. Baupost Group LLC MA raised its holdings in shares of Bristol-Myers Squibb by 225.0% during the second quarter. Baupost Group LLC MA now owns 13,000,000 shares of the biopharmaceutical company’s stock valued at $589,550,000 after buying an additional 9,000,000 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Bristol-Myers Squibb by 67.6% during the second quarter. Renaissance Technologies LLC now owns 20,698,607 shares of the biopharmaceutical company’s stock valued at $938,682,000 after buying an additional 8,347,432 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Bristol-Myers Squibb by 6.7% during the second quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after buying an additional 7,178,698 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Bristol-Myers Squibb by 75.7% during the second quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock valued at $732,691,000 after buying an additional 6,960,047 shares during the last quarter. 80.90% of the stock is currently owned by institutional investors.

NYSE:BMY traded up $0.23 during midday trading on Tuesday, hitting $58.38. 581,647 shares of the stock were exchanged, compared to its average volume of 13,093,408. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $58.46. The company has a market capitalization of $94.53 billion, a price-to-earnings ratio of 14.67, a P/E/G ratio of 1.35 and a beta of 0.71. The business has a 50-day moving average price of $53.20 and a two-hundred day moving average price of $48.32. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm had revenue of $6.01 billion for the quarter, compared to analysts’ expectations of $5.89 billion. During the same quarter in the previous year, the company earned $1.09 earnings per share. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. Sell-side analysts forecast that Bristol-Myers Squibb Co will post 4.33 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 2.81%. Bristol-Myers Squibb’s payout ratio is 41.21%.

A number of research firms have recently weighed in on BMY. Wolfe Research set a $66.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, November 1st. Bank of America began coverage on Bristol-Myers Squibb in a report on Wednesday, October 16th. They set a “buy” rating and a $60.00 price target on the stock. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Peel Hunt reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a report on Tuesday, October 29th. Finally, ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Buy” and a consensus price target of $56.64.

In related news, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the sale, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: Capital Gains Distribution

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.